The laboratory of Dr. Chang Kim, recently published a high-impact study that elucidates the bone marrow niche and mechanisms by which innate lymphoid cells differentiate between those which remain in the bone marrow and those which emigrate to the rest of the body. Read more[...]
As the SARS-CoV-2 virus continues to mutate over time and new booster vaccines become available, the question arises, are the multivalent boosters more effective at improving immune response than the monovalent vaccines with which we began? This question was addressed by a multi-site group from Columbia University Vagelos College of Physicians and Surgeons (New York) and from the University of Michigan Medical School Department of Pathology. Drs. Riccardo Valdez, Carmen Gherasim, and Aubree Gordon represented the Immunity Associated with SARS-CoV-2 (IASO) research team at U-M[...]
The American Board of Pathology (ABPath) is pleased to announce the appointment of May Chan, MD to the ABPath’s Test Development and Advisory Committee (TDAC) for Dermatopathology beginning in 2023. The TDACs are responsible for developing and reviewing the ABPath certification exam questions that assess and certify a physician’s education, knowledge, experience, and skills in order to provide high-quality care in the pathology profession. "As an established subject matter expert in dermatopathology, the contributions of Dr. Chan will be highly valued," commented Bonnie Woodworth, ABP Communications Director.
One of the most fascinating aspects of a career in cancer research is that one never knows when or where the next great discovery will occur. This was true of a recent breakthrough discovery made by the Dr. Russell Ryan laboratory at the University of Michigan Medical School. They were shocked to find that active regulatory elements in B-ALL contained not only typical protein binding sequences but also simple repeats of the sequence “GGAA”, usually considered a form of “junk DNA” with no regulatory function [...]
The University of Michigan Rogel Cancer Center researchers received one of the Prostate Cancer Foundation’s four inaugural Class of 2022 TACTICAL (Therapy ACceleration To Intercept Cancer Lethality) Award. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer [...]
Members of the University of Michigan Department of Pathology and Michigan Center for Translational Pathology, in collaboration with the Clinical Proteomic Tumor Analysis Consortium, recently published a large study on clear cell renal cell carcinomas (ccRCCs), which represent about 75% of the RCC cases and account for the most RCC-associated deaths. This study set out to create a comprehensive profile of ccRCC, combining histologic and molecular profiles. By analyzing both the microscopic cell structures and the genetic makeup of the cells, these researchers discovered significant intratumoral heterogeneity in 90% of ccRCCs. This indicates that ccRCCs originate from multiple tumor cell lines, called tumor subclones, that may become metastatic and could independently influence response to therapies. Through this study, the team was able to molecularly stratify aggressive histopathic subtypes, which may lead to more effective treatment strategies for patients and improved survival.